Aurora Cannabis Inc. is reviewing a bid from a U.S. cannabis company aiming to acquire the Edmonton-based firm. Following Curaleaf Holdings Inc.’s disclosure of its intent to purchase all shares of Aurora, the latter announced the establishment of a special committee to assess the unsolicited offer. If successful, the acquisition would result in a merged cannabis enterprise operating in 17 countries across Europe, North America, and other global markets, Curaleaf revealed.
Curaleaf, headquartered in Stamford, Conn. and listed on the Toronto Stock Exchange, decided to make its bid public after unsuccessful private negotiations with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7, outlining the proposal and financial terms, Aurora’s board allegedly declined to engage in meaningful discussions, according to Curaleaf. The U.S. company expressed disappointment over Aurora’s lack of cooperation and emphasized its readiness to swiftly finalize a definitive agreement to advance the transaction.
Curaleaf proposed a payment of $4 US per share to Aurora shareholders, alongside an additional $0.75 US in cash for each Aurora share. In response, Aurora acknowledged receipt of the letters from Curaleaf but disputed the claim that it had ignored the offer. Aurora clarified that its lead independent director had recently corresponded with Curaleaf’s CEO and affirmed its commitment to executing its existing business strategy while remaining open to ongoing dialogue.
Aurora plans to assemble a special committee comprising independent directors to evaluate the bid’s merit and its impact on stakeholders. The company cautioned that there is no certainty of a deal being finalized and assured that its operations would continue without interruption. Despite Curaleaf’s interest, analysts from TD Cowen suggested that the current offer undervalues Aurora’s long-term potential, citing the company’s market leadership, product portfolio, financial strength, and regulatory expertise as factors that could yield greater value over time.
Curaleaf’s CEO highlighted the potential value creation from merging the companies, emphasizing the synergy between Curaleaf’s global distribution network and Aurora’s strong international medical cannabis presence. The consolidation is expected to leverage the companies’ combined revenue of over $1.5 billion US in the past year, with anticipated annual cost synergies of at least $40 million US. Jordan emphasized the benefits for shareholders, presenting them with an opportunity to participate in a diversified global platform and gain exposure to favorable U.S. regulatory trends.